Continuous prophylaxis (CP) against cytomegalovirus (CMV) is a better strategy than preemptive therapy (PT) for pancreas-kidney transplant (PKT) recipients who are CMV-seropositive, data suggest.

In a Spanish study of PKT recipients, the incidence of CMV disease in recipients who were seropositive prior to transplantation was 30% with no prophylaxis, 23% with PT, and 6.9% with CP for 12 weeks, investigators reported in Transplant Infectious Disease (2009; published online ahead of print).

Continue Reading